Molecular pathogenesis of peripheral neuroblastic tumors

Oncogene

Volumn 29, Issue 11, 2010, Pages 1566-1579

  Janoueix Lerosey, I ^a   Schleiermacher, G ^a,b   Delattre, O ^a,b  

^a INSTITUT CURIE   (France)

^b INSTITUT CURIE   (France)

Author keywords

ALK mutations; Expression profiling; Genetic alterations; Neuroblastoma; Progression; Susceptibility

Indexed keywords

3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE; ANAPLASTIC LYMPHOMA KINASE; NVP TAE 684; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ALK GENE; CANCER GROWTH; CANCER MORTALITY; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CLINICAL FEATURE; CLINICAL TRIAL; GENE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE MUTATION; GENETIC PREDISPOSITION; GENOMICS; HISTOPATHOLOGY; HUMAN; NEUROBLASTOMA; NONHUMAN; NUMERICAL CHROMOSOME ABERRATION; ONCOGENE C MYB; PRIORITY JOURNAL; REVIEW;

GENETIC HETEROGENEITY; GENETIC PREDISPOSITION TO DISEASE; HOMEODOMAIN PROTEINS; HUMANS; KAPLAN-MEIERS ESTIMATE; MUTATION; NEUROBLASTOMA; PROTEIN-TYROSINE KINASES; TRANSCRIPTION FACTORS;

EID: 77949647233     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.518     Document Type: Review

References (132)

1. Adam P, Katzenberger T, Seeberger H, Gattenlohner S, Wolf J, Steinlein C, et al. (2003). A case of a diffuse large B-cell lymphoma of plasmablastic type associated with the t(2;5)(p23;q35) chromosome translocation. Am J Surg Pathol 27: 1473-1476.
2. Adhikary S, Eilers M. (2005). Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol 6: 635-645.
3. Amiel J, Laudier B, Attie-Bitach T, Trang H, de Pontual L, Gener B, et al. (2003). Polyalanine expansion and frameshift mutations of the paired-like homeobox gene PHOX2B in Congenital Central Hypoventilation Syndrome. Nat Genet 33: 459-461.
4. Asgharzadeh S, Pique-Regi R, Sposto R, Wang H, Yang Y, Shimada H, et al. (2006). Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J Natl Cancer Inst 98: 1193-1203.
5. Attiyeh EF, London WB, Mosse YP, Wang Q, Winter C, Khazi D, et al. (2005). Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 353: 2243-2253.
6. Barrette S, Bernstein ML, Leclerc JM, Champagne MA, Samson Y, Brossard J, et al. (2006). Treatment complications in children diagnosed with neuroblastoma during a screening program. J Clin Oncol 24: 1542-1545.
7. Bentires-Alj M, Kontaridis MI, Neel BG. (2006). Stops along the RAS pathway in human genetic disease. Nat Med 12: 283-285.
8. Berwanger B, Hartmann O, Bergmann E, Bernard S, Nielsen D, Krause M, et al. (2002). Loss of a FYN-regulated differentiation and growth arrest pathway in advanced stage neuroblastoma. Cancer Cell 2: 377-386.
9. Bilsland JG, Wheeldon A, Mead A, Znamenskiy P, Almond S, Waters KA, et al. (2008). Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications. Neuropsychopharmacology 33: 685-700.
10. Bourdeaut F, Janoueix-Lerosey I, Lucchesi C, Paris R, Ribeiro A, de Pontual L, et al. (2009). Cholinergic switch associated with morphological differentiation in neuroblastoma. J Pathol 219: 463-472.
11. Bourdeaut F, Ribeiro A, Paris R, Pierron G, Couturier J, Peuchmaur M, et al. (2008). In neuroblastic tumours, Schwann cells do not harbour the genetic alterations of neuroblasts but may nevertheless share the same clonal origin. Oncogene 27: 3066-3071.
12. Bown N, Cotterill S, Lastowska M, O'Neill S, Pearson AD, Plantaz D, et al. (1999). Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 340: 1954-1961.
13. Brodeur GM. (2003). Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3: 203-216.
14. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. (1993). Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11: 1466-1477.
15. Capasso M, Devoto M, Hou C, Asgharzadeh S, Glessner JT, Attiyeh EF, et al. (2009). Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nat Genet 41: 718-723.
16. Caren H, Abel F, Kogner P, Martinsson T. (2008). High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem J 416: 153-159.
17. Caron H, Spieker N, Godfried M, Veenstra M, van Sluis P, de Kraker J, et al. (2001). Chromosome bands 1p35-36 contain two distinct neuroblastoma tumor suppressor loci, one of which is imprinted. Genes Chromosomes Cancer 30: 168-174.
18. Caron H, van Sluis P, van Roy N, de Kraker J, Speleman F, Voute PA, et al. (1994). Recurrent 1;17 translocations in human neuroblastoma reveal nonhomologous mitotic recombination during the S/G2 phase as a novel mechanism for loss of heterozygosity. Am J Hum Genet 55: 341-347.
19. Carr J, Bown NP, Case MC, Hall AG, Lunec J, Tweddle DA. (2007). High-resolution analysis of allelic imbalance in neuroblastoma cell lines by single nucleotide polymorphism arrays. Cancer Genet Cytogenet 172: 127-138.
20. Charron J, Malynn BA, Fisher P, Stewart V, Jeannotte L, Goff SP, et al. (1992). Embryonic lethality in mice homozygous for a targeted disruption of the N-myc gene. Genes Dev 6: 2248-2257.
21. Chen QR, Bilke S, Wei JS, Whiteford CC, Cenacchi N, Krasnoselsky AL, et al. (2004). cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuro-blastoma. BMC Genomics 5: 70.
22. Chen Y, Takita J, Choi YL, Kato M, Ohira M, Sanada M, et al. (2008). Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455: 971-974.
23. Chesler L, Goldenberg DD, Seales IT, Satchi-Fainaro R, Grimmer M, Collins R, et al. (2007). Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma. Cancer Res 67: 9435-9442.
24. Chiarle R, Gong JZ, Guasparri I, Pesci A, Cai J, Liu J, et al. (2003). NPM-ALK transgenic mice spontaneously develop T-cell lympho-mas and plasma cell tumors. Blood 101: 1919-1927.
25. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. (2008). The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 8: 11-23.
26. Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, et al. (2009). The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 27: 289-297.
27. Cole KA, Attiyeh EF, Mosse YP, Laquaglia MJ, Diskin SJ, Brodeur GM, et al. (2008). A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene. Mol Cancer Res 6: 735-742.
28. Denayer E, de Ravel T, Legius E. (2008). Clinical and molecular aspects of RAS related disorders. J Med Genet 45: 695-703.
29. Diskin SJ, Hou C, Glessner JT, Attiyeh EF, Laudenslager M, Bosse K, et al. (2009). Copy number variation at 1q21.1 associated with neuroblastoma. Nature 459: 987-991.
30. Eilers M, Eisenman RN. (2008). Myc's broad reach. Genes Dev 22: 2755-2766.
31. Evans AE, D'Angio GJ, Randolph J. (1971). A proposed staging for children with neuroblastoma. Children's cancer study group A. Cancer 27: 374-378.
32. Fix A, Lucchesi C, Ribeiro A, Lequin D, Pierron G, Schleiermacher G, et al. (2008). Characterization of amplicons in neuroblastoma: high-resolution mapping using DNA microarrays, relationship with outcome, and identification of overexpressed genes. Genes Chromosomes Cancer 47: 819-834.
33. Fix A, Peter M, Pierron G, Aurias A, Delattre O, Janoueix-Lerosey I. (2004). High-resolution mapping of amplicons of the short arm of chromosome 1 in two neuroblastoma tumors by microarray-based comparative genomic hybridization. Genes Chromosomes Cancer 40: 266-270.
34. Fredlund E, Ringner M, Maris JM, Pahlman S. (2008). High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma. Proc Natl Acad Sci USA 105: 14094-14099.
35. Fukuda Y, Kawasaki H, Taira K. (2005). Exploration of human miRNA target genes in neuronal differentiation. Nucleic Acids Symp Ser (Oxf) 49: 341-342.
36. Galkin AV, Melnick JS, Kim S, Hood TL, Li N, Li L, et al. (2007). Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci USA 104: 270-275.
37. George RE, Attiyeh EF, Li S, Moreau LA, Neuberg D, Li C, et al. (2007). Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays. PLoS ONE 2: e255.
38. George RE, Kenyon R, McGuckin AG, Kohl N, Kogner P, Christiansen H, et al. (1997). Analysis of candidate gene co-amplification with MYCN in neuroblastoma. Eur J Cancer 33: 2037-2042.
39. George RE, Sanda T, Hanna M, Frohling S, Luther II W, Zhang J, et al. (2008). Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455: 975-978.
40. Griffin CA, Hawkins AL, Dvorak C, Henkle C, Ellingham T, Perlman EJ. (1999). Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. Cancer Res 59: 2776-2780.
41. Heck JE, Ritz B, Hung RJ, Hashibe M, Boffetta P. (2009). The epidemiology of neuroblastoma: a review. Paediatr Perinat Epidemiol 23: 125-143.
42. Hiyama E, Iehara T, Sugimoto T, Fukuzawa M, Hayashi Y, Sasaki F, et al. (2008). Effectiveness of screening for neuroblastoma at 6 months of age: a retrospective population-based cohort study. Lancet 371: 1173-1180.
43. Janoueix-Lerosey I, Hupe P, Maciorowski Z, La Rosa P, Schleierma-cher G, Pierron G, et al. (2005). Preferential occurrence of chromosome breakpoints within early replicating regions in neuroblastoma. Cell Cycle 4: 1842-1846.
44. Janoueix-Lerosey I, Lequin D, Brugieres L, Ribeiro A, de Pontual L, Combaret V, et al. (2008). Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455: 967-970.
45. Janoueix-Lerosey I, Schleiermacher G, Michels E, Mosseri V, Ribeiro A, Lequin D, et al. (2009). Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol 27: 1026-1033.
46. Jinbo T, Iwamura Y, Kaneko M, Sawaguchi S. (1989). Coamplifica-tion of the L-myc and N-myc oncogenes in a neuroblastoma cell line. Jpn J Cancer Res 80: 299-301.
47. Knoepfler PS, Cheng PF, Eisenman RN. (2002). N-myc is essential during neurogenesis for the rapid expansion of progenitor cell populations and the inhibition of neuronal differentiation. Genes Dev 16: 2699-2712.
48. Krasnoselsky AL, Whiteford CC, Wei JS, Bilke S, Westermann F, Chen QR, et al. (2005). Altered expression of cell cycle genes distinguishes aggressive neuroblastoma. Oncogene 24: 1533-1541.
49. Ladenstein R, Ambros IM, Potschger U, Amann G, Urban C, Fink FM, et al. (2001). Prognostic significance of DNA di-tetraploidy in neuroblastoma. Med Pediatr Oncol 36: 83-92.
50. Lamant L, Pulford K, Bischof D, Morris SW, Mason DY, Delsol G, et al. (2000). Expression of the ALK tyrosine kinase gene in neuroblastoma. Am J Pathol 156: 1711-1721.
51. Laneve P, Di Marcotullio L, Gioia U, Fiori ME, Ferretti E, Gulino A, et al. (2007). The interplay between microRNAs and the neuro-trophin receptor tropomyosin-related kinase C controls proliferation of human neuroblastoma cells. Proc Natl Acad Sci USA 104: 7957-7962.
52. Lastowska M, Cullinane C, Variend S, Cotterill S, Bown N, O'Neill S, et al. (2001). Comprehensive genetic and histopathologic study reveals three types of neuroblastoma tumors. J Clin Oncol 19: 3080-3090.
53. Liu X, Mazanek P, Dam V, Wang Q, Zhao H, Guo R, et al. (2008). Deregulated Wnt/beta-catenin program in high-risk neuroblastomas without MYCN amplification. Oncogene 27: 1478-1488.
54. Look AT, Hayes FA, Nitschke R, McWilliams NB, Green AA. (1984). Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med 311: 231-235.
55. Look AT, Hayes FA, Shuster JJ, Douglass EC, Castleberry RP, Bowman LC, et al. (1991). Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 9: 581-591.
56. Malkova A, Ivanov EL, Haber JE. (1996). Double-strand break repair in the absence of RAD51 in yeast: a possible role for break-induced DNA replication. Proc Natl Acad Sci USA 93: 7131-7136.
57. Marcelis CL, Hol FA, Graham GE, Rieu PN, Kellermayer R, Meijer RP, et al. (2008). Genotype-phenotype correlations in MYCN-related Feingold syndrome. Hum Mutat 29: 1125-1132.
58. Maris JM, Hogarty MD, Bagatell R, Cohn SL. (2007). Neuroblasto-ma. Lancet 369: 2106-2120.
59. Maris JM, Mosse YP, Bradfield JP, Hou C, Monni S, Scott RH, et al. (2008). Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. N Engl J Med 358: 2585-2593.
60. Maris JM, Woods WG. (2008). Screening for neuroblastoma: a resurrected idea? Lancet 371: 1142-1143.
61. McConville C, Reid S, Baskcomb L, Douglas J, Rahman N. (2006). PHOX2B analysis in non-syndromic neuroblastoma cases shows novel mutations and genotype-phenotype associations. Am J Med Genet A 140: 1297-1301.
62. McDermott U, Iafrate AJ, Gray NS, Shioda T, Classon M, Maheswaran S, et al. (2008). Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res 68: 3389-3395.
63. Melo JV, Barnes DJ. (2007). Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 7: 441-453.
64. Meyer N, Penn LZ. (2008). Reflecting on 25 years with MYC. Nat Rev Cancer 8: 976-990.
65. Michels E, Vandesompele J, De Preter K, Hoebeeck J, Vermeulen J, Schramm A, et al. (2007). ArrayCGH-based classification of neuroblastoma into genomic subgroups. Genes Chromosomes Cancer 46: 1098-1108.
66. Miyake I, Hakomori Y, Shinohara A, Gamou T, Saito M, Iwamatsu A, et al. (2002). Activation of anaplastic lymphoma kinase is responsible for hyperphosphorylation of ShcC in neuroblastoma cell lines. Oncogene 21: 5823-5834.
67. Molenaar JJ, van Sluis P, Boon K, Versteeg R, Caron HN. (2003). Rearrangements and increased expression of cyclin D1 (CCND1) in neuroblastoma. Genes Chromosomes Cancer 36: 242-249.
68. Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, et al. (2009). The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol 27: 298-303.
69. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, et al. (1994). Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263: 1281-1284.
70. Mosse Y, Greshock J, King A, Khazi D, Weber BL, Maris JM. (2003). Identification and high-resolution mapping of a constitutional 11q deletion in an infant with multifocal neuroblastoma. Lancet Oncol 4: 769-771.
71. Mosse YP, Diskin SJ, Wasserman N, Rinaldi K, Attiyeh EF, Cole K, et al. (2007). Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression. Genes Chromosomes Cancer 46: 936-949.
72. Mosse YP, Greshock J, Margolin A, Naylor T, Cole K, Khazi D, et al. (2005). High-resolution detection and mapping of genomic DNA alterations in neuroblastoma. Genes Chromosomes Cancer 43: 390-403.
73. Mosse YP, Laudenslager M, Khazi D, Carlisle AJ, Winter CL, Rappaport E, et al. (2004). Germline PHOX2B mutation in hereditary neuroblastoma. Am J Hum Genet 75: 727-730.
74. Mosse YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, et al. (2008). Identification of ALK as a major familial neuroblas-toma predisposition gene. Nature 455: 930-935.
75. Mourali J, Benard A, Lourenco FC, Monnet C, Greenland C, Moog-Lutz C, et al. (2006). Anaplastic lymphoma kinase is a dependence receptor whose proapoptotic functions are activated by caspase cleavage. Mol Cell Biol 26: 6209-6222.
76. Munzer C, Menegaux F, Lacour B, Valteau-Couanet D, Michon J, Coze C, et al. (2008). Birth-related characteristics, congenital malformation, maternal reproductive history and neuroblastoma: the ESCALE study (SFCE). Int J Cancer 122: 2315-2321.
77. Oberthuer A, Berthold F, Warnat P, Hero B, Kahlert Y, Spitz R, et al. (2006). Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol 24: 5070-5078.
78. Ohira M, Oba S, Nakamura Y, Isogai E, Kaneko S, Nakagawa A, et al. (2005). Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblasto-mas. Cancer Cell 7: 337-350.
79. Onciu M, Behm FG, Downing JR, Shurtleff SA, Raimondi SC, Ma Z, et al. (2003). ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: report of 2 cases. Blood 102: 2642-2644.
80. Osajima-Hakomori Y, Miyake I, Ohira M, Nakagawara A, Nakagawa A, Sakai R. (2005). Biological role of anaplastic lymphoma kinase in neuroblastoma. Am J Pathol 167: 213-222.
81. Palmer RH, Vernersson E, Grabbe C, Hallberg B. (2009). Anaplastic lymphoma kinase: signalling in development and disease. Biochem J 420: 345-361.
82. Passoni L, Longo L, Collini P, Coluccia AM, Bozzi F, Podda M, et al. (2009). Mutation-independent anaplastic lymphoma kinase over-expression in poor prognosis neuroblastoma patients. Cancer Res 69: 7338-7346.
83. Pattyn A, Morin X, Cremer H, Goridis C, Brunet JF. (1999). The homeobox gene Phox2b is essential for the development of autonomic neural crest derivatives. Nature 399: 366-370.
84. Plantaz D, Vandesompele J, Van Roy N, Lastowska M, Bown N, Combaret V, et al. (2001). Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification. Int J Cancer 91: 680-686.
85. Raabe EH, Laudenslager M, Winter C, Wasserman N, Cole K, Laquaglia M, et al. (2007). Prevalence and functional consequence of PHOX2B mutations in neuroblastoma. Oncogene 27: 469-476.
86. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, et al. (2007). Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131: 1190-1203.
87. Rothenberg AB, Berdon WE, D'Angio GJ, Yamashiro DJ, Cowles RA. (2009). Neuroblastoma-remembering the three physicians who described it a century ago: James Homer Wright, William Pepper, and Robert Hutchison. Pediatr Radiol 39: 155-160.
88. Satge D, Moore SW, Stiller CA, Niggli FK, Pritchard-Jones K, Bown N, et al. (2003). Abnormal constitutional karyotypes in patients with neuroblastoma: a report of four new cases and review of 47 others in the literature. Cancer Genet Cytogenet 147: 89-98.
89. Schilling FH, Spix C, Berthold F, Erttmann R, Fehse N, Hero B, et al. (2002). Neuroblastoma screening at one year of age. N Engl J Med 346: 1047-1053.
90. Schleiermacher G, Bourdeaut F, Combaret V, Picrron G, Raynal V, Aurias A, et al. (2005). Stepwise occurrence of a complex unbalanced translocation in neuroblastoma leading to insertion of a telomere sequence and late chromosome 17q gain. Oncogene 24: 3377-3384.
91. Schleiermacher G, Janoueix-Lerosey I, Combaret V, Derre J, Couturier J, Aurias A, et al. (2003). Combined 24-color karyotyping and comparative genomic hybridization analysis indicates predominant rearrangements of early replicating chromosome regions in neuroblastoma. Cancer Genet Cytogenet 141: 32-42.
92. Schleiermacher G, Peter M, Michon J, Hugot JP, Vielh P, Zucker JM, et al. (1994). Two distinct deleted regions on the short arm of chromosome 1 in neuroblastoma. Genes Chromosomes Cancer 10: 275-281.
93. Schleiermacher G, Raynal V, Janoueix-Lerosey I, Combaret V, Aurias A, Delattre O. (2004). Variety and complexity of chromosome 17 translocations in neuroblastoma. Genes Chromosomes Cancer 39: 143-150.
94. Schneiderman J, London WB, Brodeur GM, Castleberry RP, Look AT, Cohn SL. (2008). Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group. J Clin Oncol 26: 913-918.
95. Schramm A, Schulte JH, Klein-Hitpass L, Havers W, Sieverts H, Berwanger B, et al. (2005). Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling. Oncogene 24: 7902-7912.
96. Schulte JH, Horn S, Otto T, Samans B, Heukamp LC, Eilers UC, et al. (2008). MYCN regulates oncogenic MicroRNAs in neuroblastoma. Int J Cancer 122: 699-704.
97. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, et al. (1985). Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 313: 1111-1116.
98. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B, et al. (1999). The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 86: 364-372.
99. Shojaei-Brosseau T, Chompret A, Abel A, de Vathaire F, Raquin MA, Brugieres L, et al. (2004). Genetic epidemiology of neuroblastoma: a study of 426 cases at the Institut Gustave-Roussy in France. Pediatr Blood Cancer 42: 99-105.
100. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. (2007). Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448: 561-566.
101. Soda M, Takada S, Takeuchi K, Choi YL, Enomoto M, Ueno T, et al. (2008). A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci USA 105: 19893-19897.
102. Spitz R, Oberthuer A, Zapatka M, Brors B, Hero B, Ernestus K, et al. (2006). Oligonucleotide array-based comparative genomic hybridization (aCGH) of 90 neuroblastomas reveals aberration patterns closely associated with relapse pattern and outcome. Genes Chromosomes Cancer 45: 1130-1142.
103. Stallings RL, Nair P, Maris JM, Catchpoole D, McDermott M, O'Meara A, et al. (2006). High-resolution analysis of chromosomal breakpoints and genomic instability identifies PTPRD as a candidate tumor suppressor gene in neuroblastoma. Cancer Res 66: 3673-3680.
104. Stoica GE, Kuo A, Aigner A, Sunitha I, Souttou B, Malerczyk C, et al. (2001). Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. J Biol Chem 276: 16772-16779.
105. Stoica GE, Kuo A, Powers C, Bowden ET, Sale EB, Riegel AT, et al. (2002). Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. J Biol Chem 277: 35990-35998.
106. Su WT, Alaminos M, Mora J, Cheung NK, La Quaglia MP, Gerald WL. (2004). Positional gene expression analysis identifies 12q overexpression and amplification in a subset of neuroblastomas. Cancer Genet Cytogenet 154: 131-137.
107. Tomioka N, Oba S, Ohira M, Misra A, Fridlyand J, Ishii S, et al. (2008). Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature. Oncogene 27: 441-449.
108. Trochet D, Bourdeaut F, Janoueix-Lerosey I, Deville A, de Pontual L, Schleiermacher G, et al. (2004). Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. Am J Hum Genet 74: 761-764.
109. Trochet D, Hong SJ, Lim JK, Brunet JF, Munnich A, Kim KS, et al. (2005a). Molecular consequences of PHOX2B missense, frameshift and alanine expansion mutations leading to autonomic dysfunction. Hum Mol Genet 14: 3697-3708.
110. Trochet D, Mathieu Y, Pontual L, Savarirayan R, Munnich A, Brunet JF, et al. (2009). in vitro studies of non poly alanine PHOX2B mutations argue against a loss-of-function mechanism for congenital central hypoventilation. Hum Mutat 30: E421-E431.
111. Trochet D, O'Brien LM, Gozal D, Trang H, Nordenskjold A, Laudier B, et al. (2005b). PHOX2B genotype allows for prediction of tumor risk in Congenital Central Hypoventilation Syndrome. Am J Hum Genet 76: 421-426.
112. Turner SD, Tooze R, Maclennan K, Alexander DR. (2003). Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase. Oncogene 22: 7750-7761.
113. van Bokhoven H, Celli J, van Reeuwijk J, Rinne T, Glaudemans B, van Beusekom E, et al. (2005). MYCN haploinsufficiency is associated with reduced brain size and intestinal atresias in Feingold syndrome. Nat Genet 37: 465-467.
114. van Limpt V, Schramm A, van Lakeman A, Sluis P, Chan A, van Noesel M, et al. (2004). The Phox2B homeobox gene is mutated in sporadic neuroblastomas. Oncogene 23: 9280-9288.
115. Van Roy N, Van Limbergen H, Vandesompele J, Van Gele M, Poppe B, Salwen H, et al. (2001). Combined M-FISH and CGH analysis allows comprehensive description of genetic alterations in neuro-blastoma cell lines. Genes Chromosomes Cancer 32: 126-135.
116. Van Roy N, Vandesompele J, Menten B, Nilsson H, De Smet E, Rocchi M, et al. (2006). Translocation-excision-deletion-amplifica-tion mechanism leading to nonsyntenic coamplification of MYC and ATBF1. Genes Chromosomes Cancer 45: 107-117.
117. Vandepoele K, Andries V, Van Roy N, Staes K, Vandesompele J, Laureys G, et al. (2008). A constitutional translocation t(1;17)(p36.2;q11.2) in a neuroblastoma patient disrupts the human NBPF1 and ACCN1 genes. PLoS One 3: e2207.
118. Vandepoele K, Van Roy N, Staes K, Speleman F, van Roy F. (2005). A novel gene family NBPF: intricate structure generated by gene duplications during primate evolution. Mol Biol Evol 22: 2265-2274.
119. Vandesompele J, Baudis M, De Preter K, Van Roy N, Ambros P, Bown N, et al. (2005). Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma. J Clin Oncol 23: 2280-2299.
120. Vermeulen J, De Preter K, Naranjo A, Vercruysse L, Van Roy N, Hellemans J, et al. (2009). Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol 10: 663-671.
121. Vita M, Henriksson M. (2006). The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol 16: 318-330.
122. Wang Q, Diskin S, Rappaport E, Attiyeh E, Mosse Y, Shue D, et al. (2006). Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res 66: 6050-6062.
123. Webb TR, Slavish J, George RE, Look AT, Xue L, Jiang Q, et al. (2009). Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev Anticancer Ther 9: 331-356.
124. Wei JS, Song YK, Durinck S, Chen QR, Cheuk AT, Tsang P, et al. (2008). The MYCN oncogene is a direct target of miR-34a. Oncogene 27: 5204-5213.
125. Weinstein IB. (2002). Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 297: 63-64.
126. Weinstein IB, Joe A. (2008). Oncogene addiction. Cancer Res 68: 3077-3080; discussion 3080.
127. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM. (1997). Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 16: 2985-2995.
128. Welch C, Chen Y, Stallings RL. (2007). MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 26: 5017-5022.
129. Westermann F, Muth D, Benner A, Bauer T, Henrich KO, Oberthuer A, et al. (2008). Distinct transcriptional MYCN/cFMYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Genome Biol 9: R150.
130. Wimmer K, Zhu XX, Lamb BJ, Kuick R, Ambros PF, Kovar H, et al. (1999). Co-amplification of a novel gene, NAG, with the N-myc gene in neuroblastoma. Oncogene 18: 233-238.
131. Yamamoto K, Ohta S, Ito E, Hayashi Y, Asami T, Mabuchi O, et al. (2002). Marginal decrease in mortality and marked increase in incidence as a result of neuroblastoma screening at 6 months of age: cohort study in seven prefectures in Japan. J Clin Oncol 20: 1209-1214.
132. Zou HY, Li Q, Lee JH, Arango ME, McDonnell SR, Yamazaki S, et al. (2007). An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through anti-proliferative and antiangiogenic mechanisms. Cancer Res 67: 4408-4417.